Loading...
Market
Global Approval Count for Quartet Nanocage Vaccine by 2025
4
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Global pharmaceutical regulation updates and WHO announcements
Story
Cambridge Uni's 'Quartet Nanocage' Vaccine Targets All Coronaviruses
May 6, 2024, 03:25 PM
Researchers at Cambridge University have developed a groundbreaking vaccine technology, known as proactive vaccinology, which offers protection against a wide range of coronaviruses, including those not yet discovered. This new approach utilizes a 'quartet nanocage' structure to build immunity against potential future pathogens. The vaccine has shown effectiveness in mice and is designed to preemptively combat the threats of upcoming pandemics.
View original story
Similar markets
Less than 20 countries • 33%
20-50 countries • 34%
More than 50 countries • 33%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Adopted in 1-5 countries • 25%
Adopted in 6-10 countries • 25%
Adopted in 11-20 countries • 25%
Adopted in 21 or more countries • 25%
1-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
more than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
USA • 25%
UK • 25%
China • 25%
Canada • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 33%
10 to 20 • 33%
More than 20 • 33%
Over 50 countries • 25%
30-50 countries • 25%
10-29 countries • 25%
Under 10 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
None • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%